Zeisberg, MichaelMichaelZeisbergZeisberg, Elisabeth M.Elisabeth M.Zeisberg2018-11-072018-11-072015https://resolver.sub.uni-goettingen.de/purl?gro-2/36148Among gliptins, linagliptin is unique, because decreased glomerular filtration rate does not require dose reduction. Linagliptin was originally developed to lower blood glucose by inhibiting dipeptidyl peptidase-4 (DPP-4). However, DPP-4 has numerous additional substrates, and thus gliptins possess a vast range of additional off-target effects. Shi et al. report that linagliptin directly targets interaction of DPP-4 with integrin beta 1, preventing endothelial-mesenchymal transition and ultimately renal fibrosis, providing additional rationale for use of linagliptin in diabetic nephropathy.journal_article10.1038/ki.2015.17526323066000361079800002